{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:52:59Z","timestamp":1787878379961,"version":"build-2784847793"},"reference-count":27,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Objective: This review explores ketamine\u2019s expanding role in managing both chronic pain and mental health conditions, focusing on its pharmacologic mechanisms, clinical applications, and therapeutic potential. We assess its analgesic properties, FDA-approved application in the form of Spravato (esketamine) for depression, and off-label use for analgesia and psychiatric disorders. Methods: A systematic search of PubMed, Cochrane Library, and Scopus databases identified studies on ketamine\u2019s efficacy and safety in chronic pain and psychiatric disorders. The analysis included randomized controlled trials (RCTs), observational studies, and systematic reviews. Results: Ketamine has demonstrated significant efficacy in managing chronic pain in neuropathic pain, fibromyalgia, and complex regional pain syndrome (CRPS), especially in treatment-resistant cases. Mental health comorbidities are common in chronic pain populations, with up to 50% experiencing depression or anxiety. Ketamine\u2019s N-methyl-D-aspartate (NMDA) receptor antagonism not only underlies its analgesic effects but also contributes to rapid antidepressant responses in treatment-resistant depression (TRD) and acute suicidal ideation, as evidenced by its FDA-approved formulation, Spravato (esketamine). Beyond depression, emerging evidence supports ketamine\u2019s potential use in anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and certain substance use disorders. However, its psychomimetic effects, safety concerns, and unclear long-term impact warrant careful clinical oversight. Conclusion: Ketamine presents a versatile therapeutic strategy for managing chronic pain and a wide range of mental health disorders, signifying its potential to bridge the gap in treatment-resistant cases. Ongoing research is needed to optimize dosing strategies, assess long-term safety, and integrate ketamine into multidisciplinary care models. This approach emphasizes personalized patient care and comprehensive monitoring to navigate the complexities of coexisting chronic pain and mental health challenges.<\/jats:p>","DOI":"10.31083\/jin26766","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T08:58:32Z","timestamp":1754470712000},"source":"Crossref","is-referenced-by-count":2,"title":["Beyond Anesthesia: Ketamine\u2019s Expanding Role in Chronic Pain and Psychiatric Disorders"],"prefix":"10.31083","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0053-2402","authenticated-orcid":true,"given":"Christopher","family":"Zaki","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Division of Chronic Pain Management, University of Arizona College of Medicine Tucson, Tucson, AZ 85724, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Grant IS, Nimmo WS, McNicol LR, Clements JA. Ketamine disposition in children and adults. British Journal of Anaesthesia. 1983; 55: 1107\u20131111.","DOI":"10.1093\/bja\/55.11.1107"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Apkarian AV, Sosa Y, Krauss BR, Thomas PS, Fredrickson BE, Levy RE, et al. Chronic pain patients are impaired on an emotional decision-making task. Pain. 2004; 108: 129\u2013136.","DOI":"10.1016\/j.pain.2003.12.015"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014; 71: 681\u2013688.","DOI":"10.1001\/jamapsychiatry.2014.62"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research. 2018; 7: 659.","DOI":"10.12688\/f1000research.14344.1"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006; 63: 856\u2013864.","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bell RF, Kalso EA. Ketamine for pain management. Pain Reports. 2018; 3: e674.","DOI":"10.1097\/PR9.0000000000000674"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Medicine. 2016; 22: 238\u2013249.","DOI":"10.1038\/nm.4050"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Domino EF. Taming the ketamine tiger. 1965. Anesthesiology. 2010; 113: 678\u2013684.","DOI":"10.1097\/ALN.0b013e3181ed09a2"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Annals of Emergency Medicine. 2011; 57: 449\u2013461.","DOI":"10.1016\/j.annemergmed.2010.11.030"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. The American Journal of Psychiatry. 2018; 175: 620\u2013630.","DOI":"10.1176\/appi.ajp.2018.17060720"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. The Lancet. Psychiatry. 2018; 5: 65\u201378.","DOI":"10.1016\/S2215-0366(17)30272-9"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Aleksandrova LR, Anthony GP. Neuroplasticity as a Convergent Mechanism of Ketamine and Classical Psychedelics. Trends in Pharmacological Sciences. 2021; 42 : 929\u2013942.","DOI":"10.1016\/j.tips.2021.08.003"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). The International Journal of Neuropsychopharmacology. 2019; 22: 616\u2013630.","DOI":"10.1093\/ijnp\/pyz039"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Rzepecka A, Morgan CJA, Platt B, Mohr C, Curran HV, Leech R, et al. Spontaneous and deliberate control of mental imagery during dissociative states induced by ketamine: An fMRI investigation. NeuroImage: Clinical. 2020; 25: 102158.","DOI":"10.1016\/j.nicl.2019.102158"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475: 91\u201395.","DOI":"10.1038\/nature10130"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Bell RF, Kalso EA. Ketamine for pain management. Pain Reports. 2018; 3: e674.","DOI":"10.1097\/PR9.0000000000000674"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Coyle CM, Laws KR. Ketamine as a treatment for depression: A review. Drug and Alcohol Dependence. 2016; 173: 78\u201385.","DOI":"10.1016\/j.drugalcdep.2016.03.017"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neuroscience & Therapeutics. 2013; 19: 370\u2013380.","DOI":"10.1111\/cns.12099"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Glue P, Medlicott NJ, Harland S, Neehoff S, Anderson-Fahey B, Le Nedelec M, et al. Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology (Oxford, England). 2017; 31: 1302\u20131305.","DOI":"10.1177\/0269881117705089"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Wolff K, Winstock AR. Ketamine: from medicine to misuse. CNS Drugs. 2006; 20: 199\u2013218.","DOI":"10.2165\/00023210-200620030-00003"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Michelet D, Guervilly C, Hilly J, Adnet F. Efficacy and safety of ketamine in chronic pain management: A meta-analysis of randomized controlled trials. Pain. 2017; 158: 284\u2013295.","DOI":"10.1097\/j.pain.0000000000000772"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Efficacy and safety of intranasal esketamine in treatment resistant depression: A systematic review. Journal of Affective Disorders. 2020; 276: 372\u2013383.","DOI":"10.1016\/j.jad.2020.07.045"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychological Bulletin. 2007; 133: 581\u2013624.","DOI":"10.1037\/0033-2909.133.4.581"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. British Journal of Clinical Pharmacology. 2014; 77: 357\u2013367.","DOI":"10.1111\/bcp.12094"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Gureje O, Von Korff M, Kola L, Demyttenaere K, He Y, Posada-Villa J, et al. The relation between multiple pains and mental disorders: results from the World Mental Health Surveys. Pain. 2008; 135: 82\u201391.","DOI":"10.1016\/j.pain.2007.05.005"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesthesia and Analgesia. 2003; 97: 1730\u20131739.","DOI":"10.1213\/01.ANE.0000086618.28845.9B"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (New York, NY). 2010; 329: 959\u2013964.","DOI":"10.1126\/science.1190287"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/24\/7\/10.31083\/JIN26766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T08:58:33Z","timestamp":1754470713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/24\/7\/10.31083\/JIN26766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"alternative-id":["S0219-6352(25)00916-7"],"URL":"https:\/\/doi.org\/10.31083\/jin26766","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"article-number":"26766"}}